Payment overview · 2025
General Payments
$714.24
39 reported records · 14 companies
Healthcare provider profile · identity verified
Khaled Shafiei, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROE, LA · NPI 1922034487
Verified facts
What the public records show
CMS Open Payments records show Khaled Shafiei, MD received $714.24 in general payments during 2025 across 39 reported records.
ACADIA Pharmaceuticals Inc accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Linzess, Nuplazid, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Viberzi by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuplazid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $147.97 | 20.7% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.05 | 14.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.41 | 12.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.29 | 9.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.34 | 7.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.90 | 6.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.89 | 6.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.30 | 5.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.21 | 4.4% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $25.78 | 3.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.14 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.65 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.22 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.09 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.24 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $147.97 | 10 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.05 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $68.29 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $53.34 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.90 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 256 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 106 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 149 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
149 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
167 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1020 | 216 |
| Eliquis | Apixaban | 859 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 800 | 148 |
| Gabapentin | Gabapentin | 764 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 697 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 665 | 155 |
| Famotidine | Famotidine | 614 | 121 |
| Furosemide | Furosemide | 612 | 126 |
| Potassium Chloride | Potassium Chloride | 567 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 510 | 156 |
| Losartan Potassium | Losartan Potassium | 421 | 98 |
| Trazodone Hcl | Trazodone Hcl | 396 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 94 |
| Fluoxetine Hcl | Fluoxetine Hcl | 377 | 57 |
| Memantine Hcl | Memantine Hcl | 372 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 367 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 330 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 81 |
| Lisinopril | Lisinopril | 323 | 91 |
| Omeprazole | Omeprazole | 316 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 308 | 75 |
| Mirtazapine | Mirtazapine | 301 | 41 |
| Donepezil Hcl | Donepezil Hcl | 292 | 54 |
| Montelukast Sodium | Montelukast Sodium | 279 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 77 |
| Buspirone Hcl | Buspirone Hcl | 256 | 53 |
| Jardiance | Empagliflozin | 256 | 58 |
| Ropinirole Hcl | Ropinirole Hcl | 255 | 48 |
| Carvedilol | Carvedilol | 247 | 58 |
| Levetiracetam | Levetiracetam | 237 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 229 | 40 |
| Clonazepam | Clonazepam | 215 | 47 |
| Olanzapine | Olanzapine | 209 | 34 |
| Sertraline Hcl | Sertraline Hcl | 207 | 51 |
| Metformin Hcl | Metformin Hcl | 204 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 200 | 48 |
| Nifedipine Er | Nifedipine | 199 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 182 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 70 |
| Divalproex Sodium | Divalproex Sodium | 175 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 170 | 72 |
| Mounjaro | Tirzepatide | 167 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 69 |
| Tramadol Hcl | Tramadol Hcl | 163 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 57 |
| Allopurinol | Allopurinol | 155 | 34 |
| Meloxicam | Meloxicam | 153 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 37 |
| Linzess | Linaclotide | 149 | 40 |
| Finasteride | Finasteride | 147 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 142 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 48 |
| Prednisone | Prednisone | 138 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 136 | 33 |
| Ozempic | Semaglutide | 132 | 33 |
| Temazepam | Temazepam | 128 | 35 |
| Bumetanide | Bumetanide | 124 | 24 |
| Myrbetriq | Mirabegron | 121 | 19 |
| Aripiprazole | Aripiprazole | 118 | 19 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 117 | 32 |
| Simvastatin | Simvastatin | 114 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 23 |
| Pregabalin | Pregabalin | 113 | 23 |
| Midodrine Hcl | Midodrine Hcl | 111 | 27 |
| Kerendia | Finerenone | 106 | 24 |
| Farxiga | Dapagliflozin Propanediol | 104 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 32 |
| Glipizide | Glipizide | 94 | 23 |
| Methocarbamol | Methocarbamol | 94 | 36 |
| Azithromycin | Azithromycin | 92 | 80 |
| Rivastigmine | Rivastigmine | 92 | 11 |
| Megestrol Acetate | Megestrol Acetate | 88 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 85 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 84 | 15 |
| Risperidone | Risperidone | 83 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 43 |
| Clonidine Hcl | Clonidine Hcl | 82 | 29 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 82 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 31 |
| Lorazepam | Lorazepam | 80 | 23 |
| Sucralfate | Sucralfate | 80 | 15 |
| Digoxin | Digoxin | 79 | 11 |
| Januvia | Sitagliptin Phosphate | 77 | 17 |
| Alprazolam | Alprazolam | 75 | 19 |
| Glipizide Er | Glipizide | 71 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 14 |
| Ezetimibe | Ezetimibe | 69 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 17 |
| Colchicine | Colchicine | 66 | 17 |
| Entresto | Sacubitril/Valsartan | 65 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 51 |
| Tradjenta | Linagliptin | 63 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 52 |
| Latanoprost | Latanoprost | 59 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 23 |
| Baclofen | Baclofen | 55 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | 17 |
| Cefuroxime | Cefuroxime Axetil | 53 | 45 |
| Enalapril Maleate | Enalapril Maleate | 53 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 53 | 15 |
| Spironolactone | Spironolactone | 53 | 23 |
| Alendronate Sodium | Alendronate Sodium | 52 | 20 |
| Fluconazole | Fluconazole | 51 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 29 |
| Lacosamide | Lacosamide | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 14 |
| Atenolol | Atenolol | 45 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 36 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 12 |
| Novolog Flexpen | Insulin Aspart | 42 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Topiramate | Topiramate | 42 | 13 |
| Lubiprostone | Lubiprostone | 41 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 14 |
| Nitroglycerin | Nitroglycerin | 38 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 13 |
| Lactulose | Lactulose | 37 | 20 |
| Levofloxacin | Levofloxacin | 37 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Primidone | Primidone | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Timolol Maleate | Timolol Maleate | 34 | suppressed |
| Estradiol | Estradiol | 33 | 15 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 11 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 29 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 12 |
| Gemtesa | Vibegron | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 22 |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Nystatin | Nystatin | 26 | 18 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Valsartan | Valsartan | 24 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 15 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 16 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Viberzi | Eluxadoline | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 13 |
| Roflumilast | Roflumilast | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.24 · 39 records | ACADIA Pharmaceuticals Inc | AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, EVENITY, IBSRELA, JARDIANCE, Kerendia, Korlym, LINZESS, NUPLAZID, PROLIA, REXULTI, VRAYLAR | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error